2 completed. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow BKT140: new trials by email Literature Review of BKT140 trials Research Report on BKT140
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer CXCR4 Antagonist BL-8040, Pembrolizumab, Pharmacological Study - Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 20 | 2016-12-01 | 2025-02-19 |
| Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients BKT140 - Multiple Myeloma | Phase 1 / Phase 2 | Completed | Biokine Therapeutics Ltd | 16 | 2008-10-01 | 2011-06-10 |
Multiple Myeloma (1)
Biokine Therapeutics Ltd (1) · M.D. Anderson Cancer Center (1)
Israel (1) · United States (1)
Arnon Nagler, MD (1) · Brandon G. Smaglo, MD (1)